Relay Therapeutics, Inc. (NASDAQ: RLAY) witnessed significant activity in its options trading on Monday, with traders purchasing 5,148 call options. This figure marks an increase of approximately 1,428% compared to the typical daily volume of 337 call options, indicating heightened interest in the company’s stock.
In conjunction with this surge in options trading, shares of Relay Therapeutics traded down by 0.4%, falling by $0.04 to reach $10.32 during midday trading. A total of 583,308 shares exchanged hands, a stark contrast to the average trading volume of 2,450,851 shares. The company currently holds a market capitalization of approximately $1.84 billion, with a price-to-earnings ratio of -6.36 and a beta of 1.55. Over the past twelve months, the stock has seen a low of $1.77 and a high of $11.49.
Recent Earnings Performance and Analyst Insights
Relay Therapeutics recently released its quarterly earnings data on February 26, 2024. The company reported earnings per share of ($0.32), surpassing analysts’ consensus estimates of ($0.38) by $0.06. Revenue for the quarter reached $7.00 million, significantly exceeding analyst projections of $4.34 million.
Looking ahead, analysts forecast that Relay Therapeutics will report earnings per share of ($2.55) for the current fiscal year. This positive outlook has attracted the attention of various institutional investors, with many making adjustments to their positions in the company.
In the first quarter, AQR Capital Management LLC increased its stake in Relay Therapeutics by 11.9%, acquiring 38,812 additional shares, bringing its total holdings to 364,946 shares, valued at approximately $956,000. Other notable investors include MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd., which lifted its position by 6.6%, and Millennium Management LLC, which increased its stake by 14.6%, now owning 2,942,875 shares worth about $7.71 million.
Market Analysts Adjust Targets for Relay Therapeutics
Research analysts have been actively evaluating Relay Therapeutics, with several recent reports influencing market perceptions. Oppenheimer upgraded the stock from a “market perform” rating to an “outperform” rating, setting a price target of $14.00. Meanwhile, Guggenheim raised their price objective from $15.00 to $22.00, assigning a “buy” rating.
Weiss Ratings reiterated a “sell (d-)” rating, while Wells Fargo & Company increased their target price from $13.00 to $15.00, giving the stock an “overweight” rating. Currently, one analyst has rated Relay Therapeutics as a Strong Buy, four have given it a Buy rating, and one has issued a Sell rating. According to data from MarketBeat.com, the company holds a consensus rating of “Moderate Buy” with an average target price of $16.80.
Relay Therapeutics, based in Cambridge, Massachusetts, is a clinical-stage biotechnology company dedicated to developing precision therapies for oncology. Founded in 2016, the company employs a unique scientific platform aimed at targeting dynamic protein motion. Its operations combine computational modeling and experimental validation to discover small-molecule drug candidates capable of addressing disease-associated proteins.
As Relay Therapeutics continues to innovate and attract investor interest, the coming months will be crucial in determining its market trajectory and potential for growth.
